Clinical Trials Browser

Unknown × Lymphoma × spartalizumab × Clear all

NCT03991559 2019-08-28

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Phase 1 Unknown

Lymphoma, Neoplasm Metastasis